Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Safety
  4. Fast Track Articles
  5. Fast Track Article
image of Carbamazepine-induced Stevens-Johnson Syndrome: A Case Report with Review of the Literature

Abstract

Background

Stevens-Johnson Syndrome (SJS) is an infrequent yet severe mucocutaneous reaction that involves less than 10% of the Body Surface Area (BSA). It is predominantly induced by certain medications, including anticonvulsants (., Lamotrigine, Carbamazepine, Phenytoin, Phenobarbitone), Allopurinol at doses above 100 mg per day, and sulphonamides (., Cotrimoxazole, Sulfasalazine). Genetic predispositions, particularly the presence of the HLA-B*1502 allele, significantly increase the risk of developing SJS. This case report discusses a unique presentation of SJS in a young female patient, emphasizing the critical need for genetic screening and careful monitoring when prescribing Carbamazepine, especially in populations at higher genetic risk.

Case Presentation

A 19-year-old female patient, who had been on Phenytoin and Sodium Valproate for epilepsy management over the past year, was newly prescribed Carbamazepine. Within a week of initiating Carbamazepine, the patient experienced a seizure, followed by the sudden onset of fever, painful sores, and blisters covering the upper body, along with mucous discharge from both eyes. These symptoms rapidly worsened. Based on clinical presentations and the extent of epidermal detachment, the patient was diagnosed with SJS. The severity and mortality risks were assessed using the SCORTEN score. Therapeutic interventions included intravenous Ranitidine, Ondansetron, Paracetamol, Midazolam, Levetiracetam, and Dexamethasone, along with oral Fluconazole, Chlorpheniramine tablets, and Ciprofloxacin eye drops. The patient showed significant improvement and was discharged after fourteen days with follow-up advice.

Conclusion

This case underscores the critical importance of performing genetic testing for the HLA-B*1502 allele and conducting baseline blood tests before initiating Carbamazepine therapy. Such precautionary measures can significantly mitigate the risk of severe adverse reactions like SJS. This report adds to the scientific literature by highlighting the potential dangers associated with anticonvulsant therapies and the necessity for personalized medicine approaches in preventing life-threatening conditions. The main takeaway is the pivotal role of genetic screening and vigilant monitoring in the management of patients requiring anticonvulsant medications to prevent serious adverse reactions.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863328893241018101435
2024-11-05
2025-01-27

  • From This Site

    /content/journals/cds/10.2174/0115748863328893241018101435
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. French L.E. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol. Int. 2006 55 1 9 16 10.2332/allergolint.55.9 17075281
    [Google Scholar]
  2. Lerch M. Mainetti C. Terziroli Beretta-Piccoli B. Harr T. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Clin. Rev. Allergy Immunol. 2018 54 1 147 176 10.1007/s12016‑017‑8654‑z 29188475
    [Google Scholar]
  3. Shrestha A.B. Shrestha S. Yadav P.K. Adhikari L. Yadav A. Cefixime induced Steven Johnson syndrome: A case report from Bangladesh. Ann. Med. Surg. (Lond.) 2022 79 104089 10.1016/j.amsu.2022.104089 35860067
    [Google Scholar]
  4. Aquino M. Rosner G. Systemic Contact Dermatitis. Clin. Rev. Allergy Immunol. 2019 56 1 9 18 10.1007/s12016‑018‑8686‑z 29766368
    [Google Scholar]
  5. Chang B.L. Liu J.R. Chang S.H. See L.C. Impact on carbamazepine usage and cutaneous adverse reactions before and after the reimbursement of HLA‐B*1502 genotyping in Taiwan, 2000-2017: A nationwide longitudinal study. Epilepsia 2023 64 10 2679 2689 10.1111/epi.17726 37506179
    [Google Scholar]
  6. Yang S.C. Hu S. Zhang S.Z. Corrigendum to “The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China”. J. Immunol. Res. 2018 2018 1 3 10.1155/2018/4154507 30050956
    [Google Scholar]
  7. Frey N. Jossi J. Bodmer M. The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK. J. Invest. Dermatol. 2017 137 6 1240 1247 10.1016/j.jid.2017.01.031 28202399
    [Google Scholar]
  8. Wasuwanich P. So J.M. Chakrala T.S. Chen J. Motaparthi K. Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States and factors predictive of outcome. JAAD Int 2023 13 17 25 10.1016/j.jdin.2023.06.014 37575514
    [Google Scholar]
  9. Su S.C. Mockenhaupt M. Wolkenstein P. Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. J. Invest. Dermatol. 2017 137 5 1065 1073 10.1016/j.jid.2016.11.034 28011147
    [Google Scholar]
  10. Chung W.H. Wang C.W. Dao R.L. Severe cutaneous adverse drug reactions. J. Dermatol. 2016 43 7 758 766 10.1111/1346‑8138.13430 27154258
    [Google Scholar]
  11. Strużyna J. Surowiecka A. Korzeniowski T. Accuracy of SCORTEN in predicting mortality in toxic epidermal necrolysis. BMC Med. Inform. Decis. Mak. 2022 22 1 273 10.1186/s12911‑022‑02013‑2 36261833
    [Google Scholar]
  12. Ibarreta D. Elles R. Cassiman J.J. Rodriguez-Cerezo E. Dequeker E. Towards quality assurance and harmonization of genetic testing services in the European Union. Nat. Biotechnol. 2004 22 10 1230 1235 10.1038/nbt1004‑1230 15470457
    [Google Scholar]
  13. Poupětová H. Ledvinová J. Berná L. Dvořáková L. Kožich V. Elleder M. The birth prevalence of lysosomal storage disorders in the Czech Republic: Comparison with data in different populations. J. Inherit. Metab. Dis. 2010 33 4 387 396 10.1007/s10545‑010‑9093‑7 20490927
    [Google Scholar]
  14. Fakoya A.O.J. Omenyi P. Anthony P. Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis; Extensive Review of Reports of Drug-Induced Etiologies, and Possible Therapeutic Modalities. Open Access Maced. J. Med. Sci. 2018 6 4 730 738 10.3889/oamjms.2018.148 29731949
    [Google Scholar]
  15. Chung W.H. Hung S.I. Hong H.S. A marker for Stevens-Johnson syndrome. Nature 2004 428 6982 486 10.1038/428486a 15057820
    [Google Scholar]
  16. Funanage V.L. Impact of Genetic Testing on Human Health. Del. J. Public Health 2021 7 5 10 11 10.32481/djph.2021.12.005 35619978
    [Google Scholar]
  17. Katsanis S.H. Katsanis N. Molecular genetic testing and the future of clinical genomics. Nat. Rev. Genet. 2013 14 6 415 426 10.1038/nrg3493 23681062
    [Google Scholar]
  18. Lee E. Knox C. Phillips E. Prevalence of antibiotic-induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN): A systematic review and meta-analysis. J. Allergy Clin. Immunol. 2023 151 2 AB57 10.1016/j.jaci.2022.12.182
    [Google Scholar]
  19. Singh N. Phillips M. Toxic Epidermal Necrolysis: A Review of Past and Present Therapeutic Approaches. Skin Therapy Lett. 2022 27 5 7 13 36469487
    [Google Scholar]
  20. Zimmerman D. Dang N.H. Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Oncologic Critical Care. Cham Springer International Publishing 2020 267 280 10.1007/978‑3‑319‑74588‑6_195
    [Google Scholar]
  21. Mockenhaupt M. Stevens-John syndrome and toxic epidermal necrolysis: Clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin. Cutan. Med. Surg. 2014 33 1 10 16 10.12788/j.sder.0058 25037254
    [Google Scholar]
  22. Schwartz R.A. McDonough P.H. Lee B.W. Toxic epidermal necrolysis. J. Am. Acad. Dermatol. 2013 69 2 173.e1 173.e13 10.1016/j.jaad.2013.05.003 23866878
    [Google Scholar]
  23. Locharernkul C. Shotelersuk V. Hirankarn N. Pharmacogenetic screening of carbamazepine-induced severe cutaneous allergic reactions. J. Clin. Neurosci. 2011 18 10 1289 1294 10.1016/j.jocn.2010.12.054 21802305
    [Google Scholar]
  24. McCormack M. Alfirevic A. Bourgeois S. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 2011 364 12 1134 1143 10.1056/NEJMoa1013297 21428769
    [Google Scholar]
  25. Nasir S.A. Tan H.L. Tan H.J. Hussaini H.M. Ramli R. Stevens-Johnson Syndrome following Failure of Genetic Screening prior to Carbamazepine Prescription. Case Rep. Dent. 2017 2017 1 5 10.1155/2017/4201357 28473929
    [Google Scholar]
  26. Roujeau J.C. Stern R.S. Severe adverse cutaneous reactions to drugs. N. Engl. J. Med. 1994 331 19 1272 1285 10.1056/NEJM199411103311906 7794310
    [Google Scholar]
  27. Noe M.H. Micheletti R.G. Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis. Clin. Dermatol. 2020 38 6 607 612 10.1016/j.clindermatol.2020.06.016 33341195
    [Google Scholar]
  28. Cefalu J.E. Barrier K.M. Davis A.H. Wound Infections in Critical Care. Crit. Care Nurs. Clin. North Am. 2017 29 1 81 96 10.1016/j.cnc.2016.09.009 28160959
    [Google Scholar]
  29. Liang S.Y. Theodoro D.L. Schuur J.D. Marschall J. Infection prevention in the emergency department. Ann. Emerg. Med. 2014 64 3 299 313 10.1016/j.annemergmed.2014.02.024 24721718
    [Google Scholar]
  30. Le H.G. Saeed H. Mantagos I.S. Mitchell C.M. Goverman J. Chodosh J. Burn unit care of Stevens Johnson syndrome/toxic epidermal necrolysis: A survey. Burns 2016 42 4 830 835 10.1016/j.burns.2015.12.001 26810444
    [Google Scholar]
  31. Wall V. Yen M.T. Yang M.E.I-C.H.U.A.N. Huang A.J.W. Pflugfelder S.C. Management of the late ocular sequelae of Stevens-Johnson syndrome. Ocul. Surf. 2003 1 4 192 201 10.1016/S1542‑0124(12)70014‑9 17075650
    [Google Scholar]
  32. Schneider J.A. Cohen P.R. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. Adv. Ther. 2017 34 6 1235 1244 10.1007/s12325‑017‑0530‑y 28439852
    [Google Scholar]
  33. Creamer D. Walsh S.A. Dziewulski P. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. J. Plast. Reconstr. Aesthet. Surg. 2016 69 6 736 741 10.1016/j.bjps.2016.04.018 27216885
    [Google Scholar]
  34. Xu L.Q. Zhao X.X. Wang P.X. Yang J. Yang Y.M. Multidisciplinary treatment of a patient with necrotizing fasciitis caused by Staphylococcus aureus: A case report. World J. Clin. Cases 2019 7 21 3595 3602 10.12998/wjcc.v7.i21.3595 31750343
    [Google Scholar]
  35. Franks A.G. Jr Skin manifestations of internal disease. Med. Clin. North Am. 2009 93 6 1265 1282 10.1016/j.mcna.2009.08.010 19932330
    [Google Scholar]
  36. Woolum J.A. Bailey A.M. Baum R.A. Metts E.L. A Review of the Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Adv. Emerg. Nurs. J. 2019 41 1 56 64 10.1097/TME.0000000000000225 30702535
    [Google Scholar]
  37. Shanbhag S.S. Chodosh J. Fathy C. Goverman J. Mitchell C. Saeed H.N. Multidisciplinary care in Stevens-Johnson syndrome. Ther. Adv. Chronic Dis. 2020 ••• 11 10.1177/2040622319894469 32523661
    [Google Scholar]
  38. Wojtkiewicz A. Wysocki M. Fortuna J. Chrupek M. Matczuk M. Koltan A. Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. Acta Derm. Venereol. 2008 88 4 420 421 10.2340/00015555‑0462 18709327
    [Google Scholar]
  39. Patmanidis K. Sidiras A. Dolianitis K. Combination of infliximab and high-dose intravenous immunoglobulin for toxic epidermal necrolysis: Successful treatment of an elderly patient. Case Rep. Dermatol. Med. 2012 2012 1 3 10.1155/2012/915314 23259092
    [Google Scholar]
  40. Zárate-Correa L.C. Carrillo-Gómez D.C. Ramírez-Escobar A.F. Serrano-Reyes C. Toxic epidermal necrolysis successfully treated with infliximab. J. Investig. Allergol. Clin. Immunol. 2013 23 1 61 63 23653980
    [Google Scholar]
  41. Kirchhof M.G. Miliszewski M.A. Sikora S. Papp A. Dutz J.P. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J. Am. Acad. Dermatol. 2014 71 5 941 947 10.1016/j.jaad.2014.07.016 25087214
    [Google Scholar]
  42. Kumar P. Kanti Das N. Cyclosporine in toxic epidermal necrolysis: A brief review of the emerging therapeutic modality. Dermatol. Online J. 2016 22 10 22 10.5070/D32210032890 28329582
    [Google Scholar]
  43. Dorafshar A.H. Dickie S.R. Cohn A.B. Antishear therapy for toxic epidermal necrolysis: An alternative treatment approach. Plast. Reconstr. Surg. 2008 122 1 154 160 10.1097/PRS.0b013e3181773d5d 18594400
    [Google Scholar]
  44. Abuzneid Y.S. Alzeerelhouseini H.I.A. Rabi D. Carbamazepine Induced Stevens-Johnson Syndrome That Developed into Toxic Epidermal Necrolysis: Review of the Literature. Case Rep. Dermatol. Med. 2022 2022 1 4 10.1155/2022/6128688 35572158
    [Google Scholar]
  45. Oliveira A. Sanches M. Selores M. Stevens-Johnson syndrome and toxic epidermal necrolysis. Acta Med. Port. 2011 24 995 1002 22863510
    [Google Scholar]
  46. Fouchard N. Bertocchi M. Roujeau J-C. Revuz J. Wolkenstein P. Bastuji-Garin S. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. J. Invest. Dermatol. 2000 115 2 149 153 10.1046/j.1523‑1747.2000.00061.x 10951229
    [Google Scholar]
  47. Hernan R. Cho M.T. Wilson A.L. Impact of patient education videos on genetic counseling outcomes after exome sequencing. Patient Educ. Couns. 2020 103 1 127 135 10.1016/j.pec.2019.08.018 31521424
    [Google Scholar]
  48. de Olazarra A.S. Wang S.X. Advances in point-of-care genetic testing for personalized medicine applications. Biomicrofluidics 2023 17 3 031501 10.1063/5.0143311 37159750
    [Google Scholar]
/content/journals/cds/10.2174/0115748863328893241018101435
Loading
Carbamazepine-induced Stevens-Johnson Syndrome: A Case Report with Review of the Literature
Bentham Science Publishers ; https://doi.org/10.2174/0115748863328893241018101435
/content/journals/cds/10.2174/0115748863328893241018101435
/content/journals/cds/10.2174/0115748863328893241018101435
Loading

Data & Media loading...


  • Article Type:     Case Report
Keywords: Carbamazepine ; stevens-johnson syndrome ; seizure ; HLA-B*1502

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test